FOLLOWUS
Chinese Medicine Meets Conventional Medicine in Targeting COVID-19 Pathophysiology,Complications and Comorbidities
- Chinese Journal of Integrative Medicine Vol. 28, Issue 7, Pages: 627-643(2022)
- Affiliations：
1.Qian Xuesen Collaborative Research Center of Astrochemistry and Space Life Sciences, Institute of Drug Discovery Technology, Ningbo University, Ningbo, Zhejiang Province (315211), China
2.Department of Biological Medicines &Shanghai Engineering Research Center of Immunotherapeutics,Fudan University School of Pharmacy, Shanghai (201203),China
3.Bioinformatics and Drug Design Group, Department of Pharmacy, National University of Singapore, (117543),Singapore
4.Medical College, Tibet University, Lhasa(850011), China
5.Department of Chemical Biology, College of Chemistry and Chemical Engineering, and The Key Laboratory for Chemical Biology of Fujian Province, Xiamen University,Xiamen, Fujian Province (361005), China
6.Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology(Ministry of Education), Department of Chemistry, Tsinghua University, Beijing (102206), China
- Author bio：
Prof. CHEN Yu-zong, E-mail: chenyuzong@nbu.edu.cn
- Funds：
DOI：10.1007/s11655-022-3573-0
CLC：Published：01 July 2022，
Published Online：18 May 2022，
Accepted：06 May 2021
Scan for full text
Shan-shan WANG, Xian ZENG, Ya-li WANG, et al. Chinese Medicine Meets Conventional Medicine in Targeting COVID-19 Pathophysiology,Complications and Comorbidities. [J]. Chinese Journal of Integrative Medicine 28(7):627-643(2022)
Shan-shan WANG, Xian ZENG, Ya-li WANG, et al. Chinese Medicine Meets Conventional Medicine in Targeting COVID-19 Pathophysiology,Complications and Comorbidities. [J]. Chinese Journal of Integrative Medicine 28(7):627-643(2022) DOI： 10.1007/s11655-022-3573-0.
摘要
目的:
2
研究中国国家卫生健康委员会推荐的中药如何调节新冠肺炎的主要失调
特别是临床观察到的并发症和合并症.
方法:
2
通过聚焦于与西药相同的有效靶点
我们研究了11种国家卫健委推荐的中药在调节新冠肺炎病理生理(炎症、病毒复制)、并发症(疼痛、头痛)和合并症(高血压、肥胖、糖尿病)方面的机制. 这些中药的草药成分及其化学成分来自于中医药信息数据库 (TCM-ID) . 化学成分作用的靶标信息和经体外试验确定的活性值来自于天然产物活性及物种来源数据库 (NPASS) . 从治疗靶点数据库 (TTD) 和DrugBank数据库中搜索针对这些靶点的已批准和临床试验药物. 靶点的通路信息从京都基因与基因组百科全书 (KEGG) 和其他文献搜索中获得.
结果:
2
总体而言
9个中药调节了新冠肺炎靶点发现研究发现的6个靶标
8个和11个中药分别调节了用于治疗新冠肺炎主要并发症和合并症的8个和6个已批准或临床试验药物的靶点.
结论:
2
国家卫健委推荐的中药针对新冠肺炎主要的病理生理学、并发症和合并症的几个靶点的协调作用
在一定程度上与西药具有共同的机制.
Abstract
Objective:
2
To investigate how the National Health Commission of China (NHCC)-recommended Chinese medicines (CMs) modulate the major maladjustments of coronavirus disease 2019 (COVID-19)
particularly the clinically observed complications and comorbidities.
Methods:
2
By focusing on the potent targets in common with the conventional medicines
we investigated the mechanisms of 11 NHCC-recommended CMs in the modulation of the major COVID-19 pathophysiology (hyperinflammations
viral replication)
complications (pain
headache) and comorbidities (hypertension
obesity
diabetes). The constituent herbs of these CMs and their chemical ingredients were from the Traditional Chinese Medicine Information Database. The experimentally-determined targets and the activity values of the chemical ingredients of these CMs were from the Natural Product Activity and Species Source Database. The approved and clinical trial drugs against these targets were searched from the Therapeutic Target Database and DrugBank Database. Pathways of the targets was obtained from Kyoto Encyclopedia of Genes and Genomes and additional literature search.
Results:
2
Overall
9 CMs modulated 6 targets discovered by the COVID-19 target discovery studies
8 and 11 CMs modulated 8 and 6 targets of the approved or clinical trial drugs for the treatment of the major COVID-19 complications and comorbidities
respectively.
Conclusion:
2
The coordinated actions of each NHCC-recommended CM against a few targets of the major COVID-19 pathophysiology
complications and comorbidities
partly have common mechanisms with the conventional medicines.
关键词
Keywords
COVID-19Chinese medicinetargettherapeutic mechanismpathophysiologycomorbidity
references
National Health Commission & National Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7).Chin Med J 2020;133:1087-1095.
Ho LTF, Chan KKH, Chung VCH, Leung TH. Highlights of traditional Chinese medicine frontline expert advice in the China national guideline for COVID-19. Eur J Integr Med 2020;36:101116.
Hu K, Guan WJ, Bi Y, Zhang W, Li L, Zhang B, et al.Efficacy and safety of Lianhuaqingwen Capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial. Phytomedicine 2020;85:153242.
Luo E, Zhang D, Luo H, Liu B, Zhao K, Zhao Y, et al.Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): an empirical study from Wuhan, Hubei Province, China. Chin Med 2020;15:34.
Redeploying plant defences. Nat Plants 2020;6:177.
Gray PE, Belessis Y. The use of traditional Chinese medicines to treat SARS-CoV-2 may cause more harm than good. Pharmacol Res 2020;156:104776.
Yang Y. Use of herbal drugs to treat COVID-19 should be with caution. Lancet 2020;395:1689-1690.
Li RF, Hou YL, Huang JC, Pan WQ, Ma QH, Shi YX, et al.Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2).Pharmacol Res 2020;156:104761.
Yang R, Liu H, Bai C, Wang Y, Zhang X, Guo R, et al.Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against coronavirus disease 2019 (COVID-19): in silico and experimental study. Pharmacol Res 2020;157:104820.
Kageyama Y, Aida K, Kawauchi K, Morimoto M, Ebisui T, Akiyama T, et al. Jinhua Qinggan Granule, a Chinese herbal medicine against COVID-19, induces rapid changes in the neutrophil/lymphocyte ratio and plasma levels of IL-6 and IFN-γ: an open-label, single-arm pilot study. World Acad Sci J 2022;4:2.
Huang YF, Bai C, He F, Xie Y, Zhou H. Review on the potential action mechanisms of Chinese medicines in treating coronavirus disease 2019 (COVID-19). Pharmacol Res 2020;158:104939.
Wang SS, Zeng X, Wang YL, Zhao YF, Chen WP, Chen YZ. East meets West in COVID-19 therapeutics. Pharmacol Res 2020;159:105008.
Gao LQ, Xu J, Chen SD. In silico screening of potential Chinese herbal medicine against COVID-19 by targeting SARS-CoV-2 3CLpro and angiotensin converting enzyme Ⅱusing molecular docking. Chin J Integr Med 2020;26:527-532.
Yu S, Wang J, Shen H. Network pharmacology-based analysis of the role of traditional Chinese herbal medicines in the treatment of COVID-19. Ann Palliat Med 2020;9:437-446.
Wang YL, Zeng X, Zhao YF, Chen WP, Chen YZ. The pros and cons of traditional Chinese medicines in the treatment of COVID-19. Pharmacol Res 2020;157:104873.
Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 2020;583:459-468.
Bojkova D, Klann K, Koch B, Widera M, Krause D, Ciesek S, et al. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. Nature 2020;583:469-472.
Jiang WY. Therapeutic wisdom in traditional Chinese medicine: a perspective from modern science. Trends Pharmacol Sci 2005;26:558-563.
Wang L, Zhang RM, Liu GY, Wei BL, Wang Y, Cai HY, et al.Chinese herbs in treatment of influenza: a randomized, double-blind, placebo-controlled trial. Respir Med 2010;104:1362-1369.
Wong W, Lam CLK, Bian XZ, Zhang ZJ, Ng ST, Tung S.Morbidity pattern of traditional Chinese medicine primary care in the Hong Kong population. Sci Rep 2017;7:7513.
Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al.Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020;77:683-690.
Kemp HI, Corner E, Colvin LA. Chronic pain after COVID-19: implications for rehabilitation. Br J Anaesth 2020;125:436-440.
Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Resp Med 2020;8:e21.
Bornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol 2020;8:546-550.
Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM,et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020;55:2000547.
Richardson S, Hirsch JS, Narasimhan M, Crawford JM,McGinn T, Davidson KW, et al. Presenting characteristics,comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area.JAMA 2020;323:2052-2059.
Woolf SH, Chapman DA, Sabo RT, Weinberger DM, Hill L.Excess deaths from COVID-19 and other causes, March-April 2020. JAMA 2020;324:510-513.
Chen X, Zhou H, Liu YB, Wang JF, Li H, Ung CY, et al.Database of traditional Chinese medicine and its application to studies of mechanism and to prescription validation. Br J Pharmacol 2006;149:1092-1103.
Zeng X, Zhang P, He W, Qin C, Chen S, Tao L, et al.NPASS: natural product activity and species source database for natural product research, discovery and tool development. Nucleic Acids Res 2018;46:D1217-D1222.
Wang Y, Zhang S, Li F, Zhou Y, Zhang Y, Wang Z, et al.Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics. Nucleic Acids Res 2020;48:D1031-D1041.
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR,et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 2018;46:D1074-D1082.
Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K.KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res 2017;45:D353-D361.
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT,Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks.Genome Res 2003;13:2498-2504.
The State Council Information Office. SCIO briefing on TCM's important role and a list of effective drugs in COVID-19 prevention and control. Accessed March 25, 2020. Available at http://english.scio.gov.cn/pressroom/2020-03/25/content_75858152_0.htmhttp://english.scio.gov.cn/pressroom/2020-03/25/content_75858152_0.htm.
Das R, Koo MS, Kim BH, Jacob ST, Subbian S, Yao J, et al.Macrophage migration inhibitory factor (MIF) is a critical mediator of the innate immune response to Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 2013;110:E2997-E3006.
Tang RZ, Zhu JJ, Yang FF, Zhang YP, Xie SA, Liu YF,et al. DNA methyltransferase 1 and Kruppel-like factor 4 axis regulates macrophage inflammation and atherosclerosis. J Mol Cell Cardiol 2019;128:11-24.
Lee PP, Fitzpatrick DR, Beard C, Jessup HK, Lehar S,Makar KW, et al. A critical role for DNMT1 and DNA methylation in T cell development, function, and survival.Immunity 2001;15:763-774.
Hertel L, Chou S, Mocarski ES. Viral and cell cycle-regulated kinases in cytomegalovirus-induced pseudomitosis and replication. PLoS Pathog 2007;3:e6.
Starokadomskyy P, Gemelli T, Rios JJ, Xing C, Wang RC,Li H, et al. DNA polymerase-alpha regulates the activation of type Ⅰ interferons through cytosolic RNA:DNA synthesis.Nat Immunol 2016;17:495-504.
Ogino T, Iwama M, Ohsawa Y, Mizumoto K. Interaction of cellular tubulin with Sendai virus M protein regulates transcription of viral genome. Biochem Biophys Res Commun 2003;311:283-293.
Naghavi MH, Walsh D. Microtubule regulation and function during virus infection. J Virol 2017;91:e00538-17.
Kamibayashi T, Maze M. Clinical uses of alpha2-adrenergic agonists. Anesthesiology 2000;93:1345-1349.
Brito R, Sheth S, Mukherjea D, Rybak LP, Ramkumar V.TRPV1: a potential drug target for treating various diseases.Cells 2014;3:517-545.
Sicuteri F. Headache as possible expression of deficiency of brain 5-hydroxytryptamine (central denervation supersensitivity). Headache 1972;12:69-72.
Vila-Pueyo M. Targeted 5-HT1F therapies for migraine.Neurotherapeutics 2018;15:291-303.
Wilkins MR, Wharton J, Grimminger F, Ghofrani HA.Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J 2008;32:198-209.
Bickerdike MJ. 5-HT2C receptor agonists as potential drugs for the treatment of obesity. Curr Top Med Chem 2003;3:885-897.
Ichimura A, Hasegawa S, Kasubuchi M, Kimura I. Free fatty acid receptors as therapeutic targets for the treatment of diabetes. Front Pharmacol 2014;5:236.
Pereira CD, Azevedo I, Monteiro R, Martins MJ. 11Beta-hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus. Diabetes Obes Metab 2012;14:869-881.
Chen S, Yang J, Wei Y, Wei X. Epigenetic regulation of macrophages: from homeostasis maintenance to host defense. Cell Mol Immunol 2020;17:36-49.
Pan MH, Chiou YS, Tsai ML, Ho CT. Anti-inflammatory activity of traditional Chinese medicinal herbs. J Tradit Complement Med 2011;1:8-24.
Tong T, Wu YQ, Ni WJ, Shen AZ, Liu S. The potential insights of traditional Chinese medicine on treatment of COVID-19. Chin Med 2020;15:51.
Teuwen LA, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nat Rev Immunol 2020;20:389-391.
Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JCT,Fogerty AE, Waheed A, et al. COVID-19 and coagulation:bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood 2020;136:489-500.
Chen J, Wang YK, Gao Y, Hu LS, Yang JW, Wang JR,et al. Protection against COVID-19 injury by Qingfei Paidu Decoction via anti-viral, anti-inflammatory activity and metabolic programming. Biomed Pharmacother 2020;129:110281.
Pan HD, Yao XJ, Wang WY, Lau HY, Liu L. Network pharmacological approach for elucidating the mechanisms of traditional Chinese medicine in treating COVID-19 patients. Pharmacol Res 2020;159:105043.
Qin C, Tan KL, Zhang CL, Tan CY, Chen YZ, Jiang YY.What does it take to synergistically combine sub-potent natural products into drug-level potent combinations? PLoS One 2012;7:e49969.
Ren X, Shao XX, Li XX, Jia XH, Song T, Zhou WY, et al.Identifying potential treatments of COVID-19 from traditional Chinese medicine (TCM) by using a data-driven approach.J Ethnopharmacol 2020;258:112932.
Luo L, Jiang J, Wang C, Fitzgerald M, Hu W, Zhou Y,et al. Analysis on herbal medicines utilized for treatment of COVID-19. Acta Pharmaceutica Sinica B 2020;10:1192-1204.
Liu J, Liu J, Shen F, Qin Z, Jiang M, Zhu J, et al. Systems pharmacology analysis of synergy of TCM: an example using saffron formula. Sci Rep 2018;8:380.
Zhang A, Sun H, Wang X. Potentiating therapeutic effects by enhancing synergism based on active constituents from traditional medicine. Phytother Res 2014;28:526-533.
Su X, Yao Z, Li S, Sun H. Synergism of Chinese herbal medicine: illustrated by Danshen Compound. Evid Based Complement Alternat Med 2016;2016:7279361.
Ma XH, Zheng CJ, Han LY, Xie B, Jia J, Cao ZW, et al.Synergistic therapeutic actions of herbal ingredients and their mechanisms from molecular interaction and network perspectives. Drug Discov Today 2009;14:579-588.
0
Views
0
Downloads
1
CSCD
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
- Tel：010-62886827, 62877592 Fax：010-62874291
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
